EGFR Inhibitors in Metastatic Anal Canal Carcinoma: A Case Series
Author Information
Author(s): Saif Muhammad W., Kontny Ewa, Syrigos Kostas N., Shahrokni Armin
Hypothesis
Can EGFR inhibitors be effective in treating anal cancer patients who have progressed after standard therapies?
Conclusion
EGFR inhibitors may play a vital role in the treatment of anal cancer, warranting further large trials to clarify their efficacy.
Supporting Evidence
- All three patients had EGFR-positive tumors with different levels of EGFR expression.
- Variable disease-free survival was observed after all recommended regimens for advanced ACC had failed.
- EGFR is a valid therapeutic target in ACC as most of these carcinomas are of squamous cell histology and often strongly express EGFR.
Takeaway
Doctors tried a new medicine called EGFR inhibitors on three patients with anal cancer that didn't get better with regular treatments, and it seemed to help some of them.
Methodology
Three cases of anal cancer patients treated with EGFR inhibitors after standard chemotherapy regimens were presented.
Limitations
The study is based on only three cases, limiting the generalizability of the findings.
Participant Demographics
Three patients: one 73-year-old Caucasian female, one 64-year-old Caucasian male, and one 51-year-old African American male.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website